School of Medicine

The Pulse

Congratulations to the following individuals for obtaining extramural funding from federal, state, and/or independent sources between November 1, 2019 and January 31, 2020!

NOTE: The Office of the Dean provided the information below to The Pulse. If there is any information that was inadvertently omitted, please contact the editor (dflock@lsuhsc.edu) and a correction will be printed in the next issue of The Pulse.

National Institutes of Health (R01):

  • Jeffrey Erickson, PhD (Neuroscience Center of Excellence)
    • “Novel Presynaptic Agents to Prevent Glutamate-Induced Neural Injury”
  • Eric Lazartigues, PhD (Department of Pharmacology and Experimental Therapeutics)
    • “Targeting ACE2 Ubiquitination for Hypertension”
  • David Lefer, PhD (Cardiovascular Center of Excellence)
    • “Roles of Endothelial and Smooth Muscle KATP Channels in Myocardial Ischemic Injury”

National Institutes of Health (R21):

  • Song Hong, PhD (Neuroscience Center of Excellence)
    • “A Novel Resolution Strategy for Chronic Inflammation and Impaired Healing of Wounds in Aging”

National Institutes of Health (R25):

  • Allison Augustus-Wallace, PhD (Department of Medicine)
    • “Inspiring Diversity to Explore the Brain in the 21st Century: The NIHNDS/LSUHSCNO, Undergraduate Diversity in Neuroscience Research Experiences”

National Institutes of Health (Contract):

  • Diptasri Mandal, PhD (Department of Genetics)
    • “Determination of Genetic Susceptibility to Lung Cancer in Families from Southern Louisiana”

Foundations and National Associations:

  • Ryan Pasternak, MD (Department of Pediatrics)
    • David and Lucile Packard Foundation
    • Strategic Planning Process

Pharmaceutical and Company Grants:

  • Sunyoung Kim, PhD (Department of Biochemistry and Molecular Biology)
    • Chosen Diagnostics
    • “Noninvasive Biomarkers for Gastrointestinal Disease in Preterm Infants”
  • Sukanthini Subbiah, MD (Department of Medicine)
    • Oncternal Therapeutics
    • “A Phase 1b-2 Study of the ROR-Targeting Monoclonal Antibody, Cirmtuzmab (UC-961 and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib) in Patients with B-Cell Lymphoid Malignancies” 
  • Peter Winsauer, PhD (Department of Pharmacology and Experimental Therapeutics)
    • Full Spectrum Omega, Inc.
    • “Examination of NEPE14 in an Animal Model of Chronic Inflammatory Pain”